Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 14/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1683396 | 0.80 | KDR (0.65) | SCN9AMETKDRCYP3A4 | |
| SCHEMBL1683401 | 0.80 | SCN9A (0.40) | SCN9AMETKDRCYP3A4CA12 | |
| SCHEMBL1226469 | 0.75 | KDR (0.61) | METKDRCYP3A4 | |
| SCHEMBL17675706 | 0.72 | CA12 (0.67) | CA12CA1CA2CA9 | |
| SCHEMBL1227475 | 0.72 | KDR (0.63) | METKDRCYP3A4MAP2K1 | |
| SCHEMBL4045888 | 0.71 | KDR (0.65) | KDRMAP2K1 | |
| SCHEMBL1227728 | 0.70 | KDR (0.53) | METKDRCYP3A4MAP2K1 | |
| SCHEMBL4459617 | 0.69 | CA12 (0.65) | CA12CA1CA2CA9 | |
| SCHEMBL15869790 | 0.69 | ALDH1A1 (0.55) | SCN9ACYP3A4CA12CA1CA2 | |
| SCHEMBL24920672 | 0.69 | CA12 (0.67) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539763-B1 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-04-13 | — | — | EP | disclosed |
| EP-1539763-A4 | AZAINDOLE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060058304-A1 | Azaindole kinase inhibitors | BHIDE RAJEEV S | 2006-03-16 | — | — | US | disclosed |
| US-6969717-B2 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| EP-1539763-A1 | AZAINDOLE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-15 | — | — | EP | disclosed |
| US-20040063707-A1 | Azaindole kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004009601-A1 | AZAINDOLE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063707-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | SCN9A 4133/4885MET 96/4885KDR 5/4885 |
| US-20060058304-A1 | Azaindole kinase inhibitors | FGFR1, FGFR2, FLT1 | SCN9A 4104/4885MET 81/4885KDR 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.